Recently, under the guidance of the academician Nanshan Zhong, the research team led by Zifeng Yang from Guangzhou Institute of Respiratory Disease and the SKLRD worked with the team of Dongguan People’s Hospital to carry out a clinical and basic research on the typical cases of covid-19 treated with Xuebijing injection. The research findings formed a paper “The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical Corona Virus Disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2”, which was accepted by Pharmacological Research (IF5.893), a journal of the first zone of international pharmacology (a zone of the SCI journal of Chinese Academy of Sciences in 2020).